Global Vertigo Treatment Market Forecast to Reach $1.6 Billion by 2030, Driven by the Rise in Benign Paroxysmal Positional Vertigo Prevalence
16 mai 2024 07h52 HE
|
Research and Markets
Dublin, May 16, 2024 (GLOBE NEWSWIRE) -- The "Vertigo Treatment Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to ResearchAndMarkets.com's offering.The...
Global Parkinson Disease Market Projected to Reach $8.8 Billion by 2030, Driven by Advancements and Growing Demand for Effective Treatments
28 mars 2024 11h41 HE
|
Research and Markets
Dublin, March 28, 2024 (GLOBE NEWSWIRE) -- The "Parkinson Disease Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to ResearchAndMarkets.com's offering. ...
Global $481 Million Motion Sickness Treatment Market, 2023-2029: Rising Demand Among Millennial Travelers for Distinctive & Exclusive Travel Experiences Driving the Market
26 juin 2023 05h18 HE
|
Research and Markets
Dublin, June 26, 2023 (GLOBE NEWSWIRE) -- The Global Motion Sickness Treatment Market, 2023-2029 report has been added to ResearchAndMarkets.com's offering.The Global Motion Sickness Treatment...
Global Cerebral Palsy Treatment Market Report to 2030 - Featuring Merz Pharmaceuticals, Pfizer, Bayer and Johnson & Johnson Among Others
16 mai 2022 07h13 HE
|
Research and Markets
Dublin, May 16, 2022 (GLOBE NEWSWIRE) -- The "Cerebral Palsy Treatment Market by Drug Type, Disease Type, Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2030" report...
2021 U.S. Parkinson's Disease Epidemiology Report: 10-year Forecasts of Parkinson's Disease Epidemiology
23 août 2021 04h18 HE
|
Research and Markets
Dublin, Aug. 23, 2021 (GLOBE NEWSWIRE) -- The "Parkinson's Disease - US Epidemiology Forecast to 2030" drug pipelines has been added to ResearchAndMarkets.com's offering. The report delivers an...
Newly Published Nonclinical Data Highlight the Role of Olumacostat Glasaretil in Sebum Inhibition
26 juin 2017 07h30 HE
|
Dermira, Inc.
MENLO PARK, Calif., June 26, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira Announces Appointment of Ian Clements as Vice President, Investor Relations
06 juin 2017 07h30 HE
|
Dermira, Inc.
MENLO PARK, Calif., June 06, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira to Present at Jefferies 2017 Global Healthcare Conference
30 mai 2017 16h05 HE
|
Dermira, Inc.
MENLO PARK, Calif., May 30, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira Announces Closing of 3.00% Convertible Senior Notes Offering
16 mai 2017 16h01 HE
|
Dermira, Inc.
MENLO PARK, Calif., May 16, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM) announced today the closing of its previously announced offering of 3.00% Convertible Senior Notes due 2022 (the...
Dermira Prices Offering of $250 Million of 3.00% Convertible Senior Notes
10 mai 2017 21h32 HE
|
Dermira, Inc.
MENLO PARK, Calif., May 10, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM) announced today the pricing of its offering of $250,000,000 aggregate principal amount of 3.00% Convertible Senior...